TD Cowen on Agios Pharma (AGIO): 'we view an extension rather than issuance of a CRL as a positive sign'
Tweet Send to a Friend
TD Cowen analyst Marc Frahm reiterated a Buy rating on Agios Pharma (NASDAQ: AGIO).The analyst comments "Today, Agios announced that ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
